A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...
The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...
